ORBIT: information for clinicians

Aims

The primary purpose of the trial is to identify whether rituximab therapy or anti-TNF therapy is more effective in improving the clinical symptoms, signs, physical function and health-related quality of life of patients with active rheumatoid arthritis.

The secondary purposes are to:

  • assess the relative cost-effectiveness of these treatments
  • prospectively evaluate the influence of mood on response to, and side-effect profile from, anti-TNF and rituximab
  • identify whether synovial immuno-histology at baseline predicts differential response to rituximab and anti-TNF therapy.

Funding

Arthritis Research UK (formerly Arthritis Research Campaign) £994k

Recruitment

We aim to recruit 302 adult patients with sero-+ve RA. The first patient was recruited at Gartnavel General Hospital on 8.4.10.

Timeline

Study duration 3yrs  

Start date  April 2010

Study eCRF

The Orbit eCRF and Web Portal

Orbit documents

Patient information sheet

Protocol

GP letter

Project Manager

Jurgen Van Melckebeke,   Glasgow Clinical Research Facility, Tennent Institute, 38 Church Street, Western Infirmary, Glasgow  G11 6NT Jurgen.Van-Melckebeke@ggc.scot.nhs.uk

Direct line: 0141 232 9521